Table 3.

Comparison of miR-21 expression in four subgroups of the case group.

Parameters	Ovarian dysfunction (n = 17)	PCOS (n = 16)	Uterine lesion s (n = 8)	Endometriosis (n = 13)	p Value
Expression of miR-21 in the serum	0.053 ± 0.005	0.055 ± 0.005	0.045 ± 0.009	0.049 ± 0.007	a: 1.000
					b: 1.000
					C: 1.000
					d: 1.000
					e: 1.000
					F: 1.000
Expression of miR-21 in the FF	0.559 ± 0.271	0.117 ± 0.035	0.269 ± 0.091	0.326 ± 0.068	a: 0.238
					b: 0.801
					C: 0.838
					d: 0.978
					e: 0.889
					F: 1.000
Expression of miR-21 in the CCs	0.575 ± 0.112	0.328 ± 0.078	0.615 ± 0.195	0.685 ± 0.109	a: 0.466
					b: 1.000
					C: 0.957
					d: 0.535
					e: 0.179
					F: 0.996

Relative miR-21 expression was compared in the serum, FF, and CCs samples in the four subgroups of the case group (ovarian dysfunction, PCOS, uterine lesions, and endometriosis). Relative expression of miR-21 was not significant between all groups based on the Anova test (p < 0.05). a: p value between ovarian dysfunction and PCOS groups, b: p value between ovarian dysfunction and Uterine lesions groups, c: p value between ovarian dysfunction and Endometriosis groups, d: p value between PCOS and Uterine lesions groups, e: p value between PCOS and Endometriosis groups, f: p value between Uterine lesions and Endometriosis groups. The results are presented as the mean ± SEM. FF follicular fluid, CCs cumulus cells.